PROTACting the kinome with covalent warheads.

Area of Science:

• Drug Discovery
• Chemical Biology
• Oncology

Background:

• Proteolysis-targeting chimeras (PROTACs) are emerging as a powerful tool for targeted protein degradation.
• There is growing interest in small molecule-based PROTACs for both intracellular pathways and cancer-related targets.

Purpose of the Study:

• To review recent advancements in PROTAC technology for targeting recalcitrant and undruggable proteins.
• To discuss the application of PROTACs in cancer therapy, including targeting tumor microenvironment and angiogenesis.
• To explore synergistic effects of PROTACs with antibodies and other small molecules.

Main Methods:

• Review of recent literature on PROTAC development and clinical trials.
• Analysis of PROTAC strategies targeting intracellular pathways, cancer cells, tumor microenvironment, and angiogenesis.
• Evaluation of PROTAC combinations with antibodies and small molecules.

Main Results:

• PROTACs show promise against undruggable proteins and have entered clinical trials.
• Small molecule PROTACs demonstrate potent effects in cancer therapy, synergizing with antibodies.
• Combinations of PROTACs with small molecules targeting undruggable proteins are under clinical investigation.

Conclusions:

• PROTACs represent a significant milestone in drug development for challenging therapeutic targets.
• Further research and clinical investigation are warranted to optimize PROTAC-based therapies.
• The future of PROTACs lies in their versatile application across various disease areas, particularly in oncology.